144 related articles for article (PubMed ID: 38309729)
21. Tumor burden of persistent disease in patients with differentiated thyroid cancer: correlation with postoperative risk-stratification and impact on outcome.
Ciappuccini R; Heutte N; Lasne-Cardon A; Saguet-Rysanek V; Leroy C; Le Hénaff V; Vaur D; Babin E; Bardet S
BMC Cancer; 2020 Aug; 20(1):765. PubMed ID: 32799836
[TBL] [Abstract][Full Text] [Related]
22. Total thyroidectomy and adjuvant radioiodine treatment independently decrease locoregional recurrence risk in childhood and adolescent differentiated thyroid cancer.
Handkiewicz-Junak D; Wloch J; Roskosz J; Krajewska J; Kropinska A; Pomorski L; Kukulska A; Prokurat A; Wygoda Z; Jarzab B
J Nucl Med; 2007 Jun; 48(6):879-88. PubMed ID: 17536106
[TBL] [Abstract][Full Text] [Related]
23. Predictors of incomplete response to therapy among Filipino patients with papillary thyroid cancer in a tertiary hospital.
Mendoza ES; Lopez AA; Valdez VA; Cunanan EC; Matawaran BJ; Kho SA; Sero-Gomez MH
J Endocrinol Invest; 2016 Jan; 39(1):55-62. PubMed ID: 26036600
[TBL] [Abstract][Full Text] [Related]
24. LONG-TERM OUTCOMES AND PROGNOSTIC FACTORS IN PATIENTS WITH DIFFERENTIATED THYROID CARCINOMA AND BONE METASTASES.
Slook O; Levy S; Slutzky-Shraga I; Tsvetov G; Robenshtok E; Shimon I; Benbassat C; Hirsch D
Endocr Pract; 2019 May; 25(5):427-437. PubMed ID: 30657361
[No Abstract] [Full Text] [Related]
25. Prognostic factors for differentiated thyroid carcinoma and review of the literature.
Zhao Y; Zhang Y; Liu XJ; Shi BY
Tumori; 2012; 98(2):233-7. PubMed ID: 22677990
[TBL] [Abstract][Full Text] [Related]
26. The Prospective Implementation of the 2015 ATA Guidelines and Modified ATA Recurrence Risk Stratification System for Treatment of Differentiated Thyroid Cancer in a Canadian Tertiary Care Referral Setting.
Wu J; Hu XY; Ghaznavi S; Kinnear S; Symonds CJ; Grundy P; Parkins VM; Sharma P; Lamb D; Khalil M; Hyrcza M; Chandarana SP; Pasieka JL; Harvey A; Warshawski J; Hart R; Deutschman M; Randall DR; Paschke R
Thyroid; 2022 Dec; 32(12):1509-1518. PubMed ID: 36226405
[No Abstract] [Full Text] [Related]
27. Delayed initial radioiodine therapy related to incomplete response in low- to intermediate-risk differentiated thyroid cancer.
Li H; Zhang YQ; Wang C; Zhang X; Li X; Lin YS
Clin Endocrinol (Oxf); 2018 Apr; 88(4):601-606. PubMed ID: 29338092
[TBL] [Abstract][Full Text] [Related]
28. In differentiated thyroid cancer, an incomplete structural response to therapy is associated with significantly worse clinical outcomes than only an incomplete thyroglobulin response.
Vaisman F; Tala H; Grewal R; Tuttle RM
Thyroid; 2011 Dec; 21(12):1317-22. PubMed ID: 22136267
[TBL] [Abstract][Full Text] [Related]
29. Course and Predictive Factors of Incomplete Response to Therapy in Low- and Intermediate-Risk Thyroid Cancer.
Alzahrani AS; Moria Y; Mukhtar N; Aljamei H; Mazi S; Albalawi L; Aljomaiah A
J Endocr Soc; 2021 Jan; 5(1):bvaa178. PubMed ID: 33367194
[TBL] [Abstract][Full Text] [Related]
30. The Frequency of Differentiated Thyroid Cancer Recurrence in 2302 Patients With Excellent Response to Primary Therapy.
Pałyga I; Rumian M; Kosel A; Albrzykowski M; Krawczyk P; Kalwat A; Gąsior-Perczak D; Walczyk A; Kuchareczko A; Kopczyński J; Chrapek M; Góźdź S; Kowalska A
J Clin Endocrinol Metab; 2024 Jan; 109(2):e569-e578. PubMed ID: 37768152
[TBL] [Abstract][Full Text] [Related]
31. Response to Therapy Assessment in Intermediate-Risk Thyroid Cancer Patients: Is Thyroglobulin Stimulation Required?
Moreno I; Hirsch D; Duskin-Bitan H; Dicker-Cohen T; Shimon I; Robenshtok E
Thyroid; 2020 Jun; 30(6):863-870. PubMed ID: 31928205
[No Abstract] [Full Text] [Related]
32. Evaluation of the 2015 ATA Guidelines in Patients With Distant Metastatic Differentiated Thyroid Cancer.
van Velsen EFS; Stegenga MT; van Kemenade FJ; Kam BLR; van Ginhoven TM; Visser WE; Peeters RP
J Clin Endocrinol Metab; 2020 Mar; 105(3):e457-65. PubMed ID: 31665318
[TBL] [Abstract][Full Text] [Related]
33. Surgery for Neck Recurrence of Differentiated Thyroid Cancer: Outcomes and Risk Factors.
Lamartina L; Borget I; Mirghani H; Al Ghuzlan A; Berdelou A; Bidault F; Deandreis D; Baudin E; Travagli JP; Schlumberger M; Hartl DM; Leboulleux S
J Clin Endocrinol Metab; 2017 Mar; 102(3):1020-1031. PubMed ID: 28359102
[TBL] [Abstract][Full Text] [Related]
34. Predictive risk factors for distant metastasis in pediatric differentiated thyroid cancer from Saudi Arabia.
Parvathareddy SK; Siraj AK; Annaiyappanaidu P; Siraj N; Al-Rasheed M; Al-Haqawi W; Qadri Z; Siddiqui K; Al-Sobhi SS; Al-Dayel F; Al-Kuraya KS
Front Endocrinol (Lausanne); 2023; 14():1228049. PubMed ID: 37867506
[TBL] [Abstract][Full Text] [Related]
35. Oncologic outcomes in patients with 1-cm to 4-cm differentiated thyroid carcinoma according to extent of thyroidectomy.
Choi JB; Lee SG; Kim MJ; Kim TH; Ban EJ; Lee CR; Lee J; Kang SW; Jeong JJ; Nam KH; Chung WY; Park CS
Head Neck; 2019 Jan; 41(1):56-63. PubMed ID: 30536465
[TBL] [Abstract][Full Text] [Related]
36. Dynamic Risk Estimates of Outcome in Chinese Patients with Well-Differentiated Thyroid Cancer After Total Thyroidectomy and Radioactive Iodine Remnant Ablation.
Shen FC; Hsieh CJ; Huang IC; Chang YH; Wang PW
Thyroid; 2017 Apr; 27(4):531-536. PubMed ID: 28007013
[TBL] [Abstract][Full Text] [Related]
37. A Follow-Up Strategy for Patients with an Excellent Response to Initial Therapy for Differentiated Thyroid Carcinoma: Less Is Better.
Jeon MJ; Kim M; Park S; Oh HS; Kim TY; Kim WB; Shong YK; Kim WG
Thyroid; 2018 Feb; 28(2):187-192. PubMed ID: 29179642
[TBL] [Abstract][Full Text] [Related]
38. Validation of dynamic risk stratification and impact of BRAF in risk assessment of thyroid cancer, a nation-wide multicenter study.
Pérez-Fernández L; Sastre J; Zafón C; Oleaga A; Castelblanco E; Capel I; Galofré JC; Guadalix-Iglesias S; De la Vieja A; Riesco-Eizaguirre G
Front Endocrinol (Lausanne); 2022; 13():1071775. PubMed ID: 36714606
[TBL] [Abstract][Full Text] [Related]
39. Disease-Specific Survival Trends for Patients Presenting with Differentiated Thyroid Cancer and Distant Metastases in the United States, 1992-2018.
Wilhelm A; Conroy PC; Calthorpe L; Shui AM; Kitahara CM; Roman SA; Sosa JA
Thyroid; 2023 Jan; 33(1):63-73. PubMed ID: 36413032
[No Abstract] [Full Text] [Related]
40. Prognostic value of post-ablation stimulated thyroglobulin in differentiated thyroid cancer patients with biochemical incomplete response: a bi-center observational study.
Wang Y; Wu J; Jiang L; Zhang X; Liu B
Endocrine; 2022 Apr; 76(1):109-115. PubMed ID: 35094313
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
